Hospital
Hospital Service District 2 of the Parish of Tangipahoa State of LA.
Hospital Service District 2 of the Parish of Tangipahoa State of LA. was paid $6.47M by Medicaid between Jan 2018 and Dec 2024, across 55 billing codes. Its largest line is 99283, emergency room visit (moderate) — 54% of everything it billed.
33Billing provider infoHOSPITAL SERVICE DISTRICT 2 OF THE PARISH OF TANGIPAHOA STATE OF LA.
AMITE, LA 70422
AMITE, LA 70422
33aNPI1003925959assigned 08/30/2006
33bProvider typeCritical Access Hospital
28Total paid$6.47M
24GClaims109,444
24DCodes billed55
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Louisiana
Rank by total paid#9 of 40
Median peer was paid$3.19M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,544 | $549K | |
| 2019 | 11,471 | $456K | |
| 2020 | 8,709 | $592K | |
| 2021 | 13,920 | $1.25M | |
| 2022 | 21,109 | $1.39M | |
| 2023 | 26,189 | $1.23M | |
| 2024incomplete | 14,502 | $998K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 54% | 19,423 | 16,746 | $3.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 7,202 | 6,261 | $1.75M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.7% | 2,290 | 1,947 | $238K |
| 80050 | General health panel | 2.7% | 4,426 | 3,891 | $172K |
| 80061 | Lipid panel | 1.4% | 8,941 | 7,703 | $90K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.4% | 3,057 | 2,588 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 1,548 | 1,359 | $84K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,306 | 2,262 | $64K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,628 | 2,319 | $62K |
| 80053 | Comprehensive metabolic panel | <1% | 8,823 | 7,364 | $61K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,358 | 4,654 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,054 | 845 | $37K |
43 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,061 | $36K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 546 | $32K |
| 99285 | Emergency room visit (most serious) | <1% | 153 | $31K |
| 84439 | <1% | 4,031 | $30K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 263 | $26K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,671 | $19K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 95 | $15K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 33 | $13K |
| 81001 | <1% | 5,957 | $12K | |
| 84481 | <1% | 1,025 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 875 | $10K |
| 71045 | Radiologic examination, chest; single view | <1% | 208 | $9K |
| 81000 | <1% | 3,167 | $8K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 136 | $7K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 522 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 66 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 813 | $6K |
| 85027 | <1% | 675 | $4K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 23 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 28 | $3K |
| 82043 | <1% | 716 | $2K | |
| 87081 | <1% | 400 | $2K | |
| 81025 | <1% | 299 | $2K | |
| 82570 | <1% | 637 | $2K | |
| 82728 | <1% | 175 | $2K | |
| 84484 | <1% | 213 | $1K | |
| 86803 | <1% | 113 | $1K | |
| 82553 | <1% | 231 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 213 | $1K |
| 83540 | <1% | 235 | $1K | |
| 82550 | <1% | 246 | $958.71 | |
| 86701 | <1% | 117 | $939.61 | |
| 83721 | <1% | 168 | $892.50 | |
| 86318 | <1% | 64 | $852.55 | |
| 83525 | <1% | 47 | $422.91 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 47 | $366.30 |
| 86756 | <1% | 16 | $254.24 | |
| 82607 | <1% | 12 | $135.72 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 18 | $135.48 |
| 82746 | <1% | 12 | $132.30 | |
| 83605 | <1% | 14 | $104.13 | |
| 83735 | <1% | 13 | $67.00 | |
| 00000 | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUGAR, EDWARD (CEO)
| Provider | Location | Paid |
|---|---|---|
| Hospital Service District 2 of the Parish of Tangipahoa State of LA. | Amite, LA | $9.59M |
| Hospital Service District 2 of the Parish of Tangipahoa State of LA. | Amite, LA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.